Silexion Therapeutics: Quiet Insider Buys Signal Long‑Term Confidence Amid Executive Stakes Growth
Insider buying signals at Silexion Therapeutics: Noy Shlomo’s steady share purchases and CEO‑level stakes hint at confidence in the RNAi pipeline, suggesting potential undervaluation and long‑term upside for investors.
3 minutes to read